医学
内科学
肝细胞癌
阿替唑单抗
危险系数
胃肠病学
置信区间
贝伐单抗
门脉高压
乙型肝炎
入射(几何)
乙型肝炎表面抗原
外科
胃肠道出血
静脉曲张
肝硬化
乙型肝炎病毒
癌症
化疗
无容量
免疫学
病毒
免疫疗法
物理
光学
作者
Kanghee Park,Hye Won Lee,Euichang Kim,Won‐Mook Choi,Danbi Lee,Ju Hyun Shim,Kang Mo Kim,Young‐Suk Lim,Han Chu Lee,Changhoon Yoo,Baek‐Yeol Ryoo,Seungbong Han,Jonggi Choi
摘要
A low platelet count, main PVI, history of GI bleeding and VNT were significant risk factors for VB in patients receiving Atezo-Bev treatment for HCC. Identifying these factors can guide clinicians in assessing and managing VB risk in clinical settings.
科研通智能强力驱动
Strongly Powered by AbleSci AI